MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Natera, Inc.

< Previous 1 2 3 4 5 Next >
Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Report its Third Quarter Results on November 6, 2025
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity
From Natera, Inc.
Via Business Wire
Tickers NTRA
Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Named to Fast Company’s Next Big Things in Tech List
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium
From Natera, Inc.
Via Business Wire
Tickers NTRA
Enrollment Tops 1,600 in Natera’s EXPAND Trial of Single Gene NIPT
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Provides Update on Patent Litigation with NeoGenomics
From Natera, Inc.
Via Business Wire
Tickers NTRA
Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation
From Natera, Inc.
Via Business Wire
Tickers NTRA
IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Reports Second Quarter 2025 Financial Results
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Report Its Second Quarter Results on August 7, 2025
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Launch of ABCSG 61 (“TEODOR”), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Medicare Coverage for Signatera™ Genome
From Natera, Inc.
Via Business Wire
Tickers NTRA
SignateraTM Genome Clinical Performance Highlighted at ASCO 2025
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Reports First Quarter 2025 Financial Results
From Natera, Inc.
Via Business Wire
Tickers NTRA
Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress
From Natera, Inc.
Via Business Wire
Tickers NTRA
Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows
From Natera, Inc.
Via Business Wire
Tickers NTRA
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story